Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELEVNASDAQ:GNTANASDAQ:IZTCNASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELEVElevation Oncology$0.33+5.5%$0.43$0.22▼$4.49$19.58M1.651.35 million shs3.46 million shsGNTAGenenta Science$3.88+1.3%$3.89$2.20▼$7.28$70.97M0.6614,887 shs4,974 shsIZTCInvizyne Technologies$11.75+3.2%$14.47$8.50▼$23.00$103.16MN/A37,647 shs2,176 shsMNOVMediciNova$1.45+3.6%$1.56$1.12▼$2.55$71.12M0.7538,756 shs5,570 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELEVElevation Oncology+5.49%+27.19%-37.12%-50.60%-92.47%GNTAGenenta Science+1.31%+0.52%-0.13%+1.84%+13.05%IZTCInvizyne Technologies+3.16%+10.33%-23.45%+12.33%+1,174,999,900.00%MNOVMediciNova+3.57%+8.61%-6.15%-22.46%-3.97%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELEVElevation Oncology3.2767 of 5 stars4.24.00.00.02.71.70.6GNTAGenenta Science2.1877 of 5 stars3.53.00.00.02.71.70.0IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMNOVMediciNova1.5154 of 5 stars3.52.00.00.02.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELEVElevation Oncology 2.30Hold$3.39923.80% UpsideGNTAGenenta Science 3.00Buy$25.00544.33% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/AMNOVMediciNova 3.00Buy$9.00520.69% UpsideCurrent Analyst Ratings BreakdownLatest ELEV, GNTA, MNOV, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025ELEVElevation OncologyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/14/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AGNTAGenenta ScienceN/AN/AN/AN/A$1.21 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AMNOVMediciNova$1M71.12N/AN/A$1.07 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELEVElevation Oncology-$45.70M-$0.81N/AN/AN/AN/A-59.73%-40.05%5/1/2025 (Estimated)GNTAGenenta Science-$12.60MN/A0.00N/AN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AMNOVMediciNova-$8.56M-$0.23N/AN/AN/AN/A-19.66%-18.63%5/8/2025 (Estimated)Latest ELEV, GNTA, MNOV, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/AMNOVMediciNova-$0.14N/AN/AN/AN/AN/A5/1/2025Q1 2025ELEVElevation Oncology-$0.20N/AN/AN/AN/AN/A3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/A2/19/2025Q4 2024MNOVMediciNova-$0.06-$0.06N/A-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELEVElevation OncologyN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELEVElevation Oncology0.4517.7717.77GNTAGenenta ScienceN/A9.31N/AIZTCInvizyne TechnologiesN/AN/AN/AMNOVMediciNovaN/A13.8816.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELEVElevation Oncology83.70%GNTAGenenta Science15.13%IZTCInvizyne TechnologiesN/AMNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipELEVElevation Oncology8.10%GNTAGenenta Science28.99%IZTCInvizyne TechnologiesN/AMNOVMediciNova14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIZTCInvizyne TechnologiesN/A6.25 millionN/AN/AMNOVMediciNova1049.05 million41.74 millionOptionableELEV, GNTA, MNOV, and IZTC HeadlinesRecent News About These CompaniesMediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.comApril 17 at 2:09 AM | marketbeat.comMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025April 14 at 7:00 PM | globenewswire.comMediciNova (NASDAQ:MNOV) Earns "Buy" Rating from D. Boral CapitalApril 11, 2025 | marketbeat.comMediciNova says first patient enrolled in EAP trial to evaluate MN-166April 9, 2025 | markets.businessinsider.comFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) PatientsApril 8, 2025 | globenewswire.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comMarch 31, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comMarch 23, 2025 | marketbeat.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comMediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MNDDecember 5, 2024 | quiverquant.comMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDDecember 5, 2024 | globenewswire.comMediciNova Inc.December 5, 2024 | wsj.comD. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy RecommendationDecember 3, 2024 | msn.comMediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finanznachrichten.deMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finance.yahoo.comMediciNova provides update in letter to stockholdersNovember 20, 2024 | markets.businessinsider.comMediciNova, Inc. Provides Corporate Update and Highlights Ongoing Clinical Trials for MN166 and Other ProgramsNovember 19, 2024 | quiverquant.comMediciNova, Inc. Receives Notice of Allowance for Patent on MN-001 Method to Decrease Triglyceride Synthesis in the LiverNovember 15, 2024 | quiverquant.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New ...November 14, 2024 | bakersfield.comMediciNova granted Notice of Allowance for MN-001 patent by USPTONovember 14, 2024 | markets.businessinsider.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the LiverNovember 14, 2024 | globenewswire.comMediciNova notified of settlement in Sanofi Novartis litigationNovember 12, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Which Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?Is Realty Income a Buy as Its Dividend Streak Grows?By Jeffrey Neal Johnson | April 14, 2025View Is Realty Income a Buy as Its Dividend Streak Grows?ELEV, GNTA, MNOV, and IZTC Company DescriptionsElevation Oncology NASDAQ:ELEV$0.33 +0.02 (+5.49%) As of 04/16/2025 04:00 PM EasternElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Genenta Science NASDAQ:GNTA$3.88 +0.05 (+1.31%) Closing price 04/16/2025 03:59 PM EasternExtended Trading$3.70 -0.18 (-4.64%) As of 07:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Invizyne Technologies NASDAQ:IZTC$11.75 +0.36 (+3.16%) As of 04/15/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.MediciNova NASDAQ:MNOV$1.45 +0.05 (+3.57%) As of 04/16/2025 04:00 PM EasternMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Eyes Breakout With Earnings on Deck Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited Viking Therapeutics Stock Pops But Struggles to Hold Gains Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Lemonade: Leveraging AI to Underwrite a Path to Profitability 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
